B Cell News and Research

RSS

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.

20 May 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

A team of scientists from Genome Institute of Singapore (GIS) of the Agency for Science, Technology and Research (A*STAR) have shown how proteins involved in controlling genes work together to carry out their functions in stem cells and demonstrated for the very first time, how they can change interaction partners to make other types of cells.

20 May 2011

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Cell phones increase testosterone level, but decrease fertility in men

Men who have been diagnosed with poor sperm quality and who are trying to have children should limit their cell phone use. Researchers have found that while cell phone use appears to increase the level of testosterone circulating in the body, it may also lead to low sperm quality and a decrease in fertility.

20 May 2011

ISCO enrolls first U.S.-based donor to establish clinical-grade human parthenogenetic stem cell bank

International Stem Cell Corporation has now enrolled the first U.S.-based donor in its program to establish a bank of clinical-grade human parthenogenetic stem cells (hpSCs) capable of being immune-matched to millions of patients.

19 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study.

19 May 2011

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

19 May 2011

Stem cells from kidneys - World first from Australian scientists

According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.

19 May 2011

Scientists identify key protein behind drug-resistant leukemia

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment.

19 May 2011

Two genes linked to worst cases of esophageal cancer

University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes.

19 May 2011

MDC researchers comprehensively quantify gene expression for the first time

How do genes control us? This fundamental question of life still remains elusive despite decades of research. Genes are blueprints for proteins, but it is the proteins that actually carry out vital functions in the body for maintaining life. Diseases such as cancer are not only characterized by altered genes, but also by disturbed protein production.

19 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Berkeley Lab scientists contribute to remarkable advance in nuclear magnetic resonance

Nuclear magnetic resonance, a scientific technique associated with outsized, very low temperature, superconducting magnets, is one of the principal tools in the chemist's arsenal, used to study everything from alcohols to proteins to such frontiers as quantum computing.

19 May 2011

A new gene expression analysis technique on a single molecule sequencer

A new gene expression technique adapted for single molecule sequencing has enabled researchers at the RIKEN Omics Science Center (OSC) to accurately and quantitatively measure gene expression levels using only 100 nanograms of total RNA. The technique, which pairs RIKEN's Cap Analysis of Gene Expression (CAGE) protocol with the Helicos(R) Genetic Analysis System developed by Helicos BioSciences Corporation, opens the door to the detailed analysis of gene expression networks and rare cell populations. In recent years, next-generation DNA sequencers have produced an increasingly detailed picture of how genes are expressed at the molecular level. The transcriptional output of these genes - the RNA copies produced from DNA - has revealed a richness of complexity in transcript structure and function, providing insights into the molecular-level properties of cancers and other diseases.

19 May 2011

Common gene fault triggers a ripple of molecular signals leading to more aggressive cervical cancer

Cancer Research UK scientists have discovered that a common gene fault in cervical cancer cells triggers a ripple of molecular signals - which makes the disease more aggressive, according to research published in The Journal of Pathology.

19 May 2011

B Cell News and Research

AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency

GIS discovery could help generate stem cells more efficiently for biomedical applications

Naltrexone improves clinical, inflammatory activity in Crohn's disease patients

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Cell phones increase testosterone level, but decrease fertility in men

ISCO enrolls first U.S.-based donor to establish clinical-grade human parthenogenetic stem cell bank

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Stem cells from kidneys - World first from Australian scientists

Scientists identify key protein behind drug-resistant leukemia

Two genes linked to worst cases of esophageal cancer

MDC researchers comprehensively quantify gene expression for the first time

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Berkeley Lab scientists contribute to remarkable advance in nuclear magnetic resonance

A new gene expression analysis technique on a single molecule sequencer

Common gene fault triggers a ripple of molecular signals leading to more aggressive cervical cancer

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News